Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016 (2016), Article ID 7157169, 7 pages
http://dx.doi.org/10.1155/2016/7157169
Research Article

Laboratory Indicators of Aggrecan Turnover in Juvenile Idiopathic Arthritis

Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Silesia, Ulica Jedności 8, 41-200 Sosnowiec, Poland

Received 13 October 2015; Revised 29 December 2015; Accepted 10 January 2016

Academic Editor: Fabrizia Bamonti

Copyright © 2016 Katarzyna Winsz-Szczotka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives. Evaluation of chondroitin sulfate (CS), as an early marker of aggrecan degradation, and chondroitin sulfate 846 epitope (CS846), as a biomarker of CS synthesis, is an attempt at answering the question whether the therapy used in juvenile idiopathic arthritis (JIA) patients contributes to the normalization of biochemical changes in aggrecan. Methods and Results. Serum levels of CS and CS846 as well as catalase (CT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) activities in erythrocyte were assessed in patients before and after treatment. In the course of JIA, aggrecan metabolism is disturbed, which is reflected by a decrease () in CS serum level and an increase () in CS846 concentration. Furthermore, increased () activities of CT, SOD, and GPx in untreated JIA patients were recorded. The anti-inflammatory treatment resulted in the normalization of CS846 level and SOD and GPx activities. In untreated patients, we have revealed a significant correlation between serum CS and CS846, CT, CRP, ESR, MMP-3, and ADAMTS-4, respectively, as well as between CS846 and CT, GPx, CRP, ESR, and TGF-β1, respectively. Conclusion. The observed changes of CS and CS846 in JIA patients indicate a further need of the therapy continuation aimed at protecting a patient from a possible disability.